BIOHIT HealthCare has introduced the GastroPanel Quick Test designed as clinical decision support for gastroscopy referrals and to improve the early detection of gastric cancer.
The test can support diagnoses of Helicobacter pylori infection, atrophic gastritis (AG), a precancerous condition, and high gastric acid output in just 15 minutes, helping to triage patients in primary care and promote early discovery and treatment of gastrointestinal disorders.
The rapid, non-invasive test can be performed on a finger-prick blood sample during a clinical appointment to investigate H. pylori infection and three stomach-specific biomarkers; pepsinogen I, pepsinogen II and gastrin-17. The easy-to-use test can detect AG with comparable accuracy to the current gold standard methods, gastroscopy and histology, at a fraction of the cost, according to BIOHIT.
Detecting AG earlier in the diagnostic pathway will help to identify patients at risk of developing gastric cancer, leading to improved prognosis as well as refining the selection of patients that require further examination.
Studies have shown GastroPanel to be highly reliable in the diagnosis of AG, with a sensitivity of 74.7 per cent and a specificity of 95.6 per cent.
Graham Johnson, Managing Director at BIOHIT, commented: “We are incredibly excited about the launch of the Gastro-Panel Quick Test across the UK. This ground-breaking test will assist GPs in the care of their patients, helping them to confidently rule out AG and make informed decisions on who to refer to secondary care for gastroscopy. This is a cost-effective solution for the healthcare system that will also help endoscopy services apply the resources they have to those who need them, so that gastric cancer and significant disease can be found earlier on.”
For more information, visit: www.biohithealthcare.co.uk
Digital issue: Please click here for more information